Weber G, Neidhardt M, Frey H, Galle K, Geiger A
Arch Dermatol Res. 1981;271(4):437-9. doi: 10.1007/BF00406689.
Sixty patients suffering from psoriasis of all clinical forms have been treated with an increased dosage of Bromocriptin. The age of the patients ranged from 20 to 72 years. Patients with contraindications for Bromocriptin were excluded from the test. In 80% a remission or reduction of psoriasis lesions was noticed. Side effects in the form of nausea, dizziness and vomiting occurred in 15%, but decreased in the course of Bromocriptin therapy.
60名患有各种临床类型银屑病的患者接受了加大剂量的溴隐亭治疗。患者年龄在20至72岁之间。有溴隐亭禁忌证的患者被排除在试验之外。80%的患者银屑病皮损出现缓解或减轻。15%的患者出现恶心、头晕和呕吐等副作用，但在溴隐亭治疗过程中有所减轻。
